Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dalfampridine
Drug ID BADD_D00574
Description Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Indications and Usage Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
Marketing Status approved
ATC Code N07XX07
DrugBank ID DB06637
KEGG ID D04127
MeSH ID D015761
PubChem ID 1727
TTD Drug ID D08YIN
NDC Product Code 10144-427; 63190-0510; 67877-444; 56125-427; 0591-2533; 65862-917; 62756-429; 63629-9450; 65862-863; 38779-3205; 42571-338; 51927-5030; 42571-275; 0378-4504; 12817-054; 46016-5042; 54382-125; 62756-038; 62991-3143; 65372-1157; 16729-292; 63190-0530; 51407-246; 0054-0479
UNII BH3B64OKL9
Synonyms 4-Aminopyridine | 4 Aminopyridine | Dalfampridine | Pymadine | VMI-103 | VMI 103 | VMI103 | 4-Aminopyridine Sustained Release | 4 Aminopyridine Sustained Release | Sustained Release, 4-Aminopyridine | Fampridine-SR | Fampridine SR
Chemical Information
Molecular Formula C5H6N2
CAS Registry Number 504-24-5
SMILES C1=CN=CC=C1N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary tract infection11.01.14.004; 20.08.02.001--
Urine abnormality20.02.01.0130.007752%Not Available
Urticaria23.04.02.001; 10.01.06.001--
Uterine polyp21.07.02.001; 16.04.02.0020.001184%Not Available
Ventricular extrasystoles02.03.04.0070.001184%Not Available
Vitamin D deficiency14.12.03.0030.002746%Not Available
Vitreous floaters06.09.01.0050.003661%
Volvulus07.13.01.0120.000538%Not Available
Vomiting07.01.07.003--
Mental status changes19.07.01.0010.002961%Not Available
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.0180.020080%Not Available
Multiple sclerosis relapse17.16.01.0030.055181%Not Available
Musculoskeletal disorder15.03.05.0250.002100%Not Available
Postictal state19.13.01.005; 17.02.04.0140.000538%Not Available
Energy increased08.01.03.0170.002100%Not Available
Hypoacusis04.02.01.0060.005491%
Bladder spasm20.02.02.0130.001830%
Muscle fatigue15.05.03.0060.002100%Not Available
Muscle tightness15.05.03.0070.006676%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.103255%Not Available
Bradyphrenia17.03.03.004; 19.10.03.0020.001184%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.013943%Not Available
Metastatic renal cell carcinoma20.01.04.005; 16.08.02.0030.000538%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.004576%
Central nervous system lesion17.02.10.0110.006191%Not Available
Systemic inflammatory response syndrome24.06.03.008; 10.02.01.008; 08.01.05.0050.000808%Not Available
Prostatomegaly21.04.01.0020.001184%Not Available
Rhinalgia22.12.03.0200.001184%Not Available
Musculoskeletal stiffness15.03.05.0270.016473%Not Available
Skin burning sensation17.02.06.009; 23.03.03.0210.001830%Not Available
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages